ipl-logo

Compound 17392

691 Words3 Pages

A new oral pharmaceutical drug for type- two diabetes had been approved for clinical use, it was called Compound 17392. Marketing companies instantly wanted to have prescribers adopt and sell the product and researchers wanted to further investigate previous reports of liver toxicity in patients. Now since paying patients to try new pharmaceutical drugs was an issue due to it appearing to interfere with clinical judgement and upholding the duty to do what is best for the patient, a new idea of furthering research for the drug came into play. The idea included recruiting a group of physicians who were in the top ten percent of prescribers for type-two diabetes. Following regulations put in place by researchers, these physicians were to enter eligible patients into the trial for Compound …show more content…

They were to report on patients’ side effects, patients use of the drug, and both patient and physician subjective evaluations. Physicians who were interested in participating in this research would be paid three hundred dollars for ever patient they entered into the study, as well as an additional three hundred for the patients who participated in a one year follow up evaluation. The payment in this case was considered compensation for physician’s time and effort. An endocrinologist who practiced in New York City, Dr. Carlos Carera, was invited to attend the two-day protocol meeting to introduce the phase four clinical trial. He was interested in the development and research since some of his patients either could not tolerate or weren’t doing well on the available drugs for diabetes. Dr. Carera’s goal seems to involve participating in research to evolve and improve drugs for type-two diabetes and to be able to benefit his patients. Yet if he agrees to participate in the trial, does the fact that he’s

Show More
Related
469 Words | 2 Pages

A doctor should always take into consideration what is best for their patients without being influenced by anyone. In Stephanie Saul’s article “Drug Makers Pay for Lunch as they Pitch” she discusses how pharmaceutical companies use free lunches as an incentive to influence Doctors to prescribe their brand drugs. Many see this situation of pharmaceutical companies purchasing meals for a Doctor’s entire office as not having any effect on the doctor’s decision to prescribe their brand. The reality is that these free lunches do influence a doctor to prescribe a certain brand drug when writing a patient’s prescription. A doctor should consider what is the best option for a patient something that is affordable and if the case is that a name brand drug is the best option it should not be influenced by the pharmaceutical company in any way.

Read More
1847 Words | 8 Pages

Shalala, the FDA (defendant) did not authorize the appellants to include the four claims on the label of the dietary supplements with the reasoning that the scientific evidence is not enough to meet the requirements of significant scientific agreement11. In response to this, the appellant argued that the FDA never explained the term significant or on what basis the FDA measures the significant evidence and thus violated their constitutional rights under First Amendment by not providing an explanation with reasoning for rejecting the appellants proposed health claims11. Also, the appellants argued that under Administrative Procedure Act the FDA is obliged to articulate a standard good deal more concrete than the undefined “significant scientific agreement”11. Therefore, the court hold that the FDA’s interpretation regarding the four claims is invalid as the FDA did not provide a valid definition of scientific

Read More
1122 Words | 5 Pages

Fear can cause some patients to feel “ treated as mere "experimental model(s)" for the studies, while others refuse to take part because of historical evidences of clinical trial fraud and misconducts known to them” (Nijhawan 134). Preconceived patient perceptions lead patients to “believe that, trials will put extra burden on them. They assume that the conventional treatment is best and they are afraid of the unknown side-effects of new treatment. Convincing and receiving an informed consent from such patient is most difficult. In some case disclosing too much information of the potential side-effects may unnecessarily scare the patient away from a potentially life-saving or life-enhancing surgery or procedure”(Nijhawan 134).

Read More
1618 Words | 7 Pages

This source is available to ensure a patient’s rights are maintained and all research is conducted in an above-board fashion. This external review is the IRB. During Truman Capote’s research, there was no IRB monitoring. There was no approval before the conduction of the study. In addition, there was no other external ethical review community to monitor the research.

Read More
738 Words | 3 Pages

If the jury hates the man being convicted, that man will be guilty even if they are actually

Read More
1439 Words | 6 Pages

Throughout history, we have seen many unethical forms of human research done, which have ultimately led to dire consequences (Brandt, Lecture 7, Slide 6). Today, ethical research tools have been put forward to determine when experimentation for human research should be allowed. Equipoise is the balance between two conflicting demands, where one demand will promote the welfare of the patient while the other demand will promote the advancement of medical knowledge (Freedman, 1987, 95). There are two types of equipoise: clinical equipoise and therapeutic equipoise. Clinical equipoise looks at the balance through the scientific community, whereas therapeutic equipoise looks at the balance through the judgment of a single physician (Weiger et al., 2013, 93).

Read More
490 Words | 2 Pages

Even though the jury sees him as

Read More
341 Words | 2 Pages

Jurors are make prejudiced by his background and other witness information.

Read More
608 Words | 3 Pages

The fact that there are numerous instances where the drug companies have been accused of frauds and cheats should make the doctors more aware and

Read More
784 Words | 4 Pages

The regulation of off-study access presents a myriad of ethical dilemmas. Patients suffering from terminal illnesses face few options – either participating in a study, or facing certain death. The choice for most patients is simple: participate in the study, even at the risk of being given the placebo, because it is the only self-benefitting situation. If they refuse to participate in the study, they will surely die, but they are given a chance to live when through accessing the drugs in the study. This is beneficial to science and the population as a whole – though a small group of people will suffer as they are given a placebo, a greater number will benefit from the data collected from the research, as well as the future FDA approval, allowing

Read More
1255 Words | 6 Pages

The medical system has even become complicit in this scheme in their own attempt to get a cut of the earnings as many times doctors will get “commissions” or are incentivized to prescribe certain drugs. Furthermore, in 1997, the FDA eased its restrictions on broadcasted Direct-to-consumer advertising (DTCA). This led to a more than 300% increase in spending on advertising by 1998 to $1.2 billion which led to another 450% increase by 2006 to approximately $5.4 billion (Ventola 2011). There are both positive and negative aspects to DTCA; but, whether beneficial or harmful, this form of advertising has undoubtedly led to increased patient drug-seeking behavior and self-diagnosis that results in greater profits for both doctors and the pharmaceutical industry. With an increased number of adults seeking medication not only for themselves, but also for their children, why would the doctors not prescribe drugs to their patients?

Read More
1208 Words | 5 Pages

Their poor values have caused extensive damage to Donald, the plaintiff. Finally the last key element in the process of ethical decision-making is How. The defendants needed to ask themselves why they did not let the public know the new chemical was not FDA approved. The three men and Novelty Now did not ask themselves what would happen if everybody followed their guidelines. If they had asked themselves these questions they would have realized they were making unethical decisions.

Read More
1833 Words | 8 Pages

In this specific case study they took a psychiatric patient, Mr. A, who had been diagnosed with depression. He had been taking anti-depressants for his condition and after seeing the patient for a while doctors had concluded

Read More
4255 Words | 18 Pages

In contrast to this viewpoint, an article and associated editorial in the New England Journal of Medicine in May 2015 emphasized the importance of pharmaceutical industry-physician interactions for the development of novel treatments, and argued that moral outrage over industry malfeasance had unjustifiably led many to overemphasize the problems created by financial conflicts of interest. In 2009 a study found that "a number of academic institutions" do not have clear guidelines for relationships between Institutional Review Boards and industry. The influence of the pharmaceutical industry on medical research has been a major cause for

Read More
920 Words | 4 Pages

Each participant gave consent to be in the study and they weren’t paid for it. The study was conducted by sending each of these people to a dermatologist once a month, every month for a year to examine the lesions. By the end of the study, four participants’ results were thrown out because they did not show up to each monthly appointment. This left the study with ninety participants and a total of 360

Read More

More about Compound 17392

Related Topics

Open Document